Malignant News and Research

RSS

Agent THZ1 shrinks human-like small cell lung tumors in mice

Small cell lung cancer - a disease for which no new drugs have been approved for many years - has shown itself vulnerable to an agent that disables part of tumor cells' basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.

9 Dec 2014

BAZ2A protein directly influences the aggressiveness of prostate cancer

A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer. This key discovery has been made by a team of scientists from the German Cancer Research Center, the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes in a study of 7,700 samples of tumor tissue.

9 Dec 2014

PRM-151 compound shows positive results for treating advanced myelofibrosis

A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.

8 Dec 2014

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

8 Dec 2014

Researchers identify new targets for future CLL therapies

Chronic lymphocytic leukemia (CLL) is among the most frequent leukemias affecting adults in Western countries. It usually occurs in older patients, does not cause any symptoms for a long time and is often only discovered by accident. Despite treatment, relapses frequently occur. The immunologists Dr. Kristina Heinig and Dr. Uta Höpken (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) and the hematologist Dr. Armin Rehm (MDC and Charité - Universitätsmedizin Berlin) have now discovered why this is so.

7 Dec 2014

Nivolumab drug highly effective for Hodgkin's lymphoma

A phase I clinical trial of nivolumab found that the immune-boosting drug is a highly effective therapy for Hodgkin's lymphoma. The multi-institution study, led by Mayo Clinic, indicated that the drug was safe and led to an 87 percent response rate in patients who had failed on other treatments.

7 Dec 2014

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM).

7 Dec 2014

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Scientists suspect role of mini-chromosomes in cancers, diseases caused by gene mutations

Cancers are due to genetic aberrations in certain cells that gain the ability to divide indefinitely. This proliferation of sick cells generates tumors, which gradually invade healthy tissue. Therefore, current therapies essentially seek to destroy cancer cells to stop their proliferation. Through high-throughput genetic sequencing of glioblastoma cells, one of the most deadly brain tumors, a team of geneticists from the University of Geneva's (UNIGE) Faculty of Medicine discovered that some of these mutations are caused by supplemental extrachromosomal DNA fragments, called double minutes, which enable cancer cells to better adapt to their environment and therefore better resist to treatments meant to destroy them.

6 Dec 2014

Malnutrition predicts long-term survival in elderly patients undergoing Whipple procedure

Malnutrition is an important factor predicting long-term survival in older patients undergoing pancreaticoduodenectomy (PD) (commonly called the Whipple procedure) to treat benign tumors and cysts of the pancreas as well as pancreatitis, according to new study results published in the December issue of the Journal of the American College of Surgeons.

6 Dec 2014

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London.

4 Dec 2014

Protein that regulates the body's sleep cycle may offer cancer protection

People who work around the clock could actually be setting themselves back, according to Virginia Tech biologists.

4 Dec 2014

Faster and more accurate method for testing new cancer drugs

Finding faster and more accurate ways to test new cancer drugs is always a priority for cancer researchers.

2 Dec 2014

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

Overcoming graft rejection is the main obstacle when it comes to stem cell regeneration or organ transplantation.

2 Dec 2014

Risk-based mammography screening can miss invasive cancers in women in their 40s

A study of breast cancers detected with screening mammography found that strong family history and dense breast tissue were commonly absent in women between the ages of 40 and 49 diagnosed with breast cancer.

2 Dec 2014

Researchers identify new genetic biomarkers that predict outcomes for patients with bowel cancer

Researchers at University of Limerick and University Hospital Limerick have identified several new genetic biomarkers which better predict outcomes for patients with bowel/colorectal cancer. The research team identified genes that are predictors of cancer recurrence and can also help to identify a patients’ suitability to specific types of chemotherapy.

1 Dec 2014

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics, Inc.today announced the acceptance of a Type II variation application for IMBRUVICA (ibrutinib) by the European Medicines Agency.

1 Dec 2014

TET1 enzyme may be important target for cancer diagnostics, treatment

Mutations in the KRAS gene have long been known to cause cancer, and about one third of solid tumors have KRAS mutations or mutations in the KRAS pathway. KRAS promotes cancer formation not only by driving cell growth and division, but also by turning off protective tumor suppressor genes, which normally limit uncontrolled cell growth and cause damaged cells to self-destruct.

27 Nov 2014

New research brings personalized cancer vaccine approach one step closer to reality

In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University School of Medicine in St. Louis has brought the approach one step closer to reality.

27 Nov 2014

Malignant News and Research

Agent THZ1 shrinks human-like small cell lung tumors in mice

BAZ2A protein directly influences the aggressiveness of prostate cancer

PRM-151 compound shows positive results for treating advanced myelofibrosis

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Researchers identify new targets for future CLL therapies

Nivolumab drug highly effective for Hodgkin's lymphoma

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Scientists suspect role of mini-chromosomes in cancers, diseases caused by gene mutations

Malnutrition predicts long-term survival in elderly patients undergoing Whipple procedure

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Protein that regulates the body's sleep cycle may offer cancer protection

Faster and more accurate method for testing new cancer drugs

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

Risk-based mammography screening can miss invasive cancers in women in their 40s

Researchers identify new genetic biomarkers that predict outcomes for patients with bowel cancer

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

TET1 enzyme may be important target for cancer diagnostics, treatment

New research brings personalized cancer vaccine approach one step closer to reality

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News